| Literature DB >> 16835051 |
David McLean1, Neil Pearce, Hilde Langseth, Paavo Jäppinen, Irena Szadkowska-Stanczyk, Bodil Persson, Pascal Wild, Reiko Kishi, Elsebeth Lynge, Paul Henneberger, Maria Sala, Kay Teschke, Timo Kauppinen, Didier Colin, Manolis Kogevinas, Paolo Boffetta.
Abstract
The objective of this study was to evaluate cancer mortality in pulp and paper industry workers exposed to chlorinated organic compounds. We assembled a multinational cohort of workers employed between 1920 and 1996 in 11 countries. Exposure to both volatile and nonvolatile organochlorine compounds was estimated at the department level using an exposure matrix. We conducted a standardized mortality ratio (SMR) analysis based on age and calendar-period-specific national mortality rates and a Poisson regression analysis. The study population consisted of 60,468 workers. Workers exposed to volatile organochlorines experienced a deficit of all-cause [SMR = 0.91; 95% confidence interval (CI), 0.89-0.93] and all-cancer (SMR = 0.93; 95% CI, 0.89-0.97) mortality, with no evidence of increased risks for any cancer of a priori interest. There was a weak, but statistically significant, trend of increasing risk of all-cancer mortality with increasing weighted cumulative exposure. A similar deficit in all-cause (SMR = 0.94; 95% CI, 0.91-0.96) and all-cancer (SMR = 0.94; 95% CI, 0.89-1.00) mortality was observed in those exposed to nonvolatile organochlorines. No excess risk was observed in cancers of a priori interest, although mortality from Hodgkin disease was elevated (SMR = 1.76; 95% CI, 1.02-2.82) . In this study we found little evidence that exposure to organochlorines at the levels experienced in the pulp and paper industry is associated with an increased risk of cancer, apart from a weak but significant association between all-cancer mortality and weighted cumulative volatile organochlorine exposure.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16835051 PMCID: PMC1513323 DOI: 10.1289/ehp.8588
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Distribution of study participants by exposure status and country.
| Volatile organochlorines | Nonvolatile organochlorines | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Never exposed | Ever exposed | High exposure | Never exposed | Ever exposed | ||||||||
| Country | Employment period | Follow-up period | No. | Person-years | No. | Person-years | No. | Person-years | No. | Person-years | No. | Person-years |
| Denmark | 1920–1992 | 1943–1993 | 1,512 | 27,258 | 5,762 | 142,519 | 2,538 | 64,274 | 2,863 | 61,791 | 4,813 | 115,777 |
| Finland | 1935–1995 | 1945–1995 | 927 | 28,048 | 6,964 | 218,387 | 653 | 13,664 | 4,022 | 124,524 | 3,180 | 97,437 |
| France | 1921–1992 | 1968–1992 | 386 | 6,009 | 3,260 | 60,402 | 36 | 764 | 2,265 | 37,902 | 2,119 | 40,811 |
| Japan | 1946–1996 | 1976–1996 | 567 | 9,880 | 1,602 | 29,520 | 129 | 2,609 | 1,097 | 19,843 | 1,221 | 22,396 |
| New Zealand | 1955–1992 | 1980–1992 | 3,396 | 34,792 | 2,583 | 27,702 | 1,155 | 12,388 | 4,635 | 47,717 | 1,067 | 11,973 |
| Norway | 1920–1993 | 1953–1993 | 2,386 | 55,430 | 16,002 | 420,322 | 4,491 | 120,494 | 9,942 | 252,707 | 6,063 | 150,908 |
| Poland | 1967–1990 | 1968–1990 | 3,538 | 50,850 | 2,399 | 37,676 | 159 | 2,902 | 4,252 | 61,350 | 1,833 | 29,421 |
| Scotland | 1920–1990 | 1955–1994 | 525 | 12,480 | 3,534 | 85,965 | 26 | 810 | 414 | 7,075 | 604 | 11,171 |
| Spain | 1955–1991 | 1970–1992 | 228 | 3,946 | 1,199 | 21,219 | 8 | 80 | 2,379 | 48,815 | 1,729 | 33,830 |
| Sweden | 1920–1990 | 1955–1991 | 969 | 17,329 | 2,475 | 53,210 | 379 | 8,323 | 728 | 16,947 | 2,151 | 53,250 |
| United States | 1920–1982 | 1961–1991 | 147 | 2,824 | 107 | 2,014 | 54 | 1,127 | 625 | 10,973 | 160 | 3,162 |
| Total | 14,581 | 248,846 | 45,887 | 1,098,936 | 9,628 | 229,434 | 33,222 | 689,645 | 24,940 | 570,135 | ||
The total number of workers that could be classified by exposure to volatile (60,468) and nonvolatile (58,162) organochlorines differed.
High exposure is a subset of ever exposure.
SMRs for selected causes by exposure to volatile organochlorine compounds.
| Never exposed | Ever exposed | High exposure | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cause of death (ICD-9 codes) | Obs | SMR | 95% CI | Obs | SMR | 95% CI | Obs | SMR | 95% CI |
| All causes | 2,175 | 0.88 | 0.84–0.91 | 9,350 | 0.91 | 0.89–0.93 | 1,902 | 0.90 | 0.86–0.95 |
| All neoplasms (140–208) | 524 | 0.91 | 0.83–0.99 | 2,285 | 0.93 | 0.89–0.97 | 517 | 1.01 | 0.93–1.10 |
| Oral cavity and pharynx (140–149) | 9 | 0.68 | 0.31–1.29 | 33 | 0.61 | 0.42–0.86 | 11 | 1.09 | 0.54–1.95 |
| Esophagus (150) | 15 | 0.99 | 0.56–1.64 | 45 | 0.74 | 0.54–0.99 | 6 | 0.57 | 0.21–1.24 |
| Stomach (151) | 60 | 0.98 | 0.75–1.26 | 201 | 0.83 | 0.72–0.95 | 43 | 0.95 | 0.69–1.28 |
| Colon (153) | 38 | 0.98 | 0.69–1.34 | 140 | 0.85 | 0.72–1.01 | 35 | 0.90 | 0.63–1.25 |
| Rectum (154) | 18 | 0.68 | 0.40–1.07 | 98 | 0.91 | 0.74–1.10 | 30 | 1.19 | 0.80–1.70 |
| Liver (155) | 10 | 0.76 | 0.37–1.41 | 33 | 0.76 | 0.53–1.07 | 6 | 0.83 | 0.31–1.82 |
| Gallbladder (156) | 6 | 1.24 | 0.45–2.69 | 14 | 0.66 | 0.36–1.10 | 4 | 1.05 | 0.29–2.70 |
| Pancreas (157) | 32 | 1.07 | 0.74–1.52 | 115 | 0.90 | 0.75–1.09 | 19 | 0.71 | 0.42–1.10 |
| Larynx (161) | 9 | 1.18 | 0.54–2.24 | 29 | 1.00 | 0.67–1.43 | 3 | 0.65 | 0.13–1.89 |
| Lung (162) | 122 | 0.85 | 0.70–1.01 | 613 | 1.04 | 0.96–1.13 | 125 | 1.06 | 0.88–1.26 |
| Pleura (163) | 4 | 1.91 | 0.52–4.90 | 20 | 2.00 | 1.22–3.09 | 8 | 3.67 | 1.58–7.23 |
| Other respiratory (164–165) | 0 | 0.00 | 0.00–2.74 | 10 | 1.72 | 0.82–3.15 | 4 | 3.84 | 1.05–9.84 |
| Soft tissue (171) | 2 | 0.88 | 0.11–3.20 | 12 | 1.13 | 0.59–1.98 | 4 | 1.75 | 0.48–4.48 |
| Melanoma (172) | 9 | 1.02 | 0.47–1.94 | 42 | 1.12 | 0.81–1.51 | 6 | 0.63 | 0.23–1.37 |
| Breast (174–175) | 4 | 0.94 | 0.26–2.41 | 63 | 0.96 | 0.73–1.22 | 6 | 0.61 | 0.22–1.32 |
| Cervix uteri (180) | 1 | 0.89 | 0.02–4.98 | 17 | 0.99 | 0.58–1.59 | 2 | 0.67 | 0.08–2.40 |
| Prostate (185) | 44 | 0.79 | 0.58–1.07 | 177 | 0.86 | 0.74–1.00 | 49 | 1.02 | 0.76–1.35 |
| Penis and other male genital organs (187) | 1 | 1.46 | 0.04–8.11 | 7 | 2.51 | 1.01–5.17 | 2 | 3.11 | 0.38–11.2 |
| Bladder (188) | 17 | 0.88 | 0.51–1.40 | 87 | 1.09 | 0.88–1.35 | 20 | 1.07 | 0.65–1.65 |
| Kidney (189) | 12 | 0.77 | 0.40–1.34 | 54 | 0.77 | 0.58–1.01 | 15 | 0.97 | 0.54–1.59 |
| Brain (191–192) | 16 | 1.02 | 0.58–1.66 | 68 | 0.98 | 0.76–1.25 | 20 | 1.25 | 0.76–1.93 |
| Lymphatic and hematopoietic (200–208) | 45 | 0.96 | 0.70–1.28 | 189 | 0.94 | 0.81–1.08 | 41 | 0.92 | 0.66–1.25 |
| NHL (200, 202) | 15 | 1.12 | 0.63–1.86 | 52 | 0.86 | 0.64–1.13 | 11 | 0.84 | 0.42–1.51 |
| Hodgkin disease (201) | 4 | 0.94 | 0.26–2.42 | 21 | 1.07 | 0.66–1.63 | 4 | 0.93 | 0.25–2.39 |
| Multiple myeloma (203) | 7 | 0.76 | 0.31–1.58 | 41 | 1.02 | 0.73–1.38 | 9 | 1.00 | 0.46–1.90 |
| Leukemia (204–208) | 19 | 0.99 | 0.60–1.55 | 75 | 0.93 | 0.73–1.17 | 17 | 0.95 | 0.55–1.51 |
| Circulatory system diseases (390–459) | 1,042 | 0.91 | 0.86–0.97 | 4,444 | 0.95 | 0.92–0.98 | 877 | 0.92 | 0.86–0.98 |
| Respiratory system diseases (460–519) | 130 | 0.77 | 0.64–0.91 | 561 | 0.82 | 0.75–0.89 | 97 | 0.72 | 0.59–0.88 |
| Digestive system diseases (520–579) | 60 | 0.71 | 0.54–0.91 | 299 | 0.85 | 0.75–0.95 | 47 | 0.68 | 0.50–0.91 |
| Liver cirrhosis (571) | 23 | 0.77 | 0.49–1.16 | 119 | 0.95 | 0.79–1.14 | 24 | 1.00 | 0.64–1.48 |
Obs, observed.
High exposure is a subset of ever exposure.
SMRs for selected causes by exposure to nonvolatile organochlorine compounds.
| Never exposed | Ever exposed | |||||
|---|---|---|---|---|---|---|
| Cause of death (ICD-9 codes) | Obs | SMR | 95% CI | Obs | SMR | 95% CI |
| All causes | 5,771 | 0.89 | 0.87–0.91 | 4,622 | 0.94 | 0.91–0.96 |
| All neoplasms (140–208) | 1,434 | 0.94 | 0.89–0.99 | 1,145 | 0.94 | 0.89–1.00 |
| Oral cavity and pharynx (140–149) | 33 | 0.92 | 0.63–1.29 | 15 | 0.51 | 0.29–0.85 |
| Esophagus (150) | 27 | 0.71 | 0.41–1.03 | 26 | 0.78 | 0.51–1.15 |
| Stomach (151) | 146 | 0.93 | 0.79–1.10 | 98 | 0.89 | 0.72–1.08 |
| Colon (153) | 106 | 1.04 | 0.85–1.25 | 62 | 0.74 | 0.57–0.95 |
| Rectum (154) | 60 | 0.87 | 0.66–1.12 | 51 | 0.96 | 0.71–1.26 |
| Liver (155) | 27 | 0.87 | 0.57–1.27 | 16 | 0.69 | 0.40–1.13 |
| Pancreas (157) | 67 | 0.84 | 0.65–1.06 | 69 | 1.12 | 0.87–1.42 |
| Larynx (161) | 18 | 0.92 | 0.54–1.45 | 20 | 1.23 | 0.75–1.90 |
| Lung (162) | 356 | 0.98 | 0.88–1.08 | 314 | 1.04 | 0.93–1.17 |
| Pleura (163) | 17 | 2.78 | 1.62–4.45 | 4 | 0.78 | 0.21–2.01 |
| Other respiratory (164–165) | 8 | 2.11 | 0.91–4.16 | 2 | 0.66 | 0.08–2.39 |
| Soft tissue (171) | 8 | 1.22 | 0.53–2.41 | 4 | 0.80 | 0.22–2.04 |
| Melanoma (172) | 20 | 0.82 | 0.50–1.27 | 21 | 1.17 | 0.72–1.78 |
| Breast (174–175) | 21 | 0.90 | 0.55–1.37 | 32 | 0.89 | 0.61–1.25 |
| Prostate (185) | 117 | 0.85 | 0.70–1.02 | 84 | 0.93 | 0.74–1.15 |
| Penis and other male genital organs (187) | 2 | 1.12 | 0.14–4.05 | 5 | 3.60 | 1.17–8.40 |
| Bladder (188) | 50 | 1.00 | 0.74–1.32 | 43 | 1.09 | 0.79–1.46 |
| Kidney (189) | 41 | 0.94 | 0.67–1.27 | 18 | 0.53 | 0.31–0.83 |
| Brain (191–192) | 44 | 1.02 | 0.74–1.37 | 28 | 0.80 | 0.53–1.15 |
| Lymphatic and hematopoietic (200–208) | 112 | 0.88 | 0.72–1.05 | 97 | 0.99 | 0.81–1.21 |
| NHL (200, 202) | 35 | 0.93 | 0.65–1.30 | 25 | 0.86 | 0.55–1.26 |
| Hodgkin disease (201) | 7 | 0.58 | 0.23–1.19 | 17 | 1.76 | 1.02–2.82 |
| Multiple myeloma (203) | 21 | 0.83 | 0.51–1.27 | 20 | 1.07 | 0.66–1.66 |
| Leukemia (204–208) | 49 | 0.95 | 0.70–1.26 | 35 | 0.89 | 0.62–1.24 |
| Circulatory system diseases (390–459) | 2,727 | 0.92 | 0.89–0.96 | 2,157 | 0.99 | 0.95–1.04 |
| Respiratory system diseases (460–519) | 327 | 0.78 | 0.69–0.86 | 266 | 0.82 | 0.72–0.92 |
| Digestive system diseases (520–579) | 167 | 0.74 | 0.63–0.86 | 166 | 0.91 | 0.77–1.05 |
Obs, observed.
Mortality from selected causes by weighted cumulative exposure to volatile organochlorines.
| Weighted cumulative exposure to volatile organochlorines | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| < 1 ppm-years | 1–17 ppm-years | > 18 ppm-years | |||||||
| Cause of death (ICD-9 codes) | Obs | RR | Obs | RR | 95% CI | Obs | RR | 95% CI | Trend |
| All neoplasms (140–208) | 1,006 | 1 | 778 | 1.12 | (1.01–1.24) | 489 | 1.19 | (1.06–1.34) | 0.002 |
| Esophagus (150) | 26 | 1 | 14 | 0.94 | (0.46–1.90) | 5 | 0.54 | (0.19–1.51) | 0.289 |
| Liver (155) | 18 | 1 | 9 | 1.05 | (0.42–2.65) | 6 | 1.45 | (0.51–4.16) | 0.525 |
| Lung (162) | 253 | 1 | 236 | 1.15 | (0.95–1.39) | 120 | 1.07 | (0.85–1.36) | 0.394 |
| Pleura (163) | 6 | 1 | 6 | 1.16 | (0.36–3.78) | 8 | 2.49 | (0.83–7.53) | 0.114 |
| Lymphatic and hematopoietic (200–208) | 90 | 1 | 66 | 1.09 | (0.78–1.54) | 33 | 0.93 | (0.61–1.42) | 0.859 |
| NHL (200, 202) | 25 | 1 | 18 | 1.15 | (0.60–2.22) | 9 | 0.97 | (0.43–2.20) | 0.955 |
Obs, observed.
Weighted cumulative exposure (∑ prevalence × level × duration).
Reference category.
RR adjusted for sex, age, employment status, calendar year, and country.
p-Value of test for linear trend.